Georgia Kokaraki

Dr. Georgia Kokaraki

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
OGOkan Gultekin
Okan Gultekin
JGJordi Gonzalez-Molina
Jordi Gonzalez-Molina
EHElin Hardell
Elin Hardell
LMLidia Moyano-Galceran
Lidia Moyano-Galceran
NMNicholas Mitsios
Nicholas Mitsios
JCJoseph Carlson
Joseph Carlson
Uterine sarcomas are rare but deadly malignancies without effective treatment. Immunotherapy is a promising new approach to treat these tumors but has shown heterogeneous effects in sarcoma patients. With the goal of identifying key factors for improved patient treatment, we characterized the tumor immune landscape in 58 uterine sarcoma cases with full clinicopathological annotation. Immune cell characterization revealed the overall prevalence of FOXP3+ cells and pro-tumor M2-like macrophages. Hierarchical clustering of patients showed four tumor type-independent immune signatures, where infiltration of FOXP3+ cells and M1-like macrophages associated with favorable prognosis. High CD8+/FOXP3+ ratio in UUS and ESS correlated with poor survival, upregulation of immunosuppressive markers, extracellular matrix (ECM)-related genes and proteins, and YAP activation. This study shows that uterine sarcomas present distinct immune signatures with prognostic value, independent of tumor type, and suggests that targeting the ECM could be beneficial for future treatments.

27 February 2025 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
JHJair Manuel Gutiérrez Herrera
Jair Manuel Gutiérrez Herrera
MMM.Angeles Montero-Fernandez
M.Angeles Montero-Fernandez
GKGeorgia Kokaraki
Georgia Kokaraki
LPLuigi De Petris
Luigi De Petris
RFRaul Falcao
Raul Falcao
COCristian Ortiz-Villalón
Cristian Ortiz-Villalón
Background/Objectives: Since the discovery of oncogenic neurotrophic receptor tyrosine kinase (NTRK) gene fusions in colorectal cancer in 1986, their understanding has evolved, particularly in non-small-cell lung cancer (NSCLC) over the past five years. NTRK rearrangements, involving NTRK1, NTRK2, and NTRK3, drive tumorigenesis and have been identified in various adult and pediatric cancers, with over 80 different fusion variants in several type of cancers. Detecting these rearrangements is crucial for targeted therapy strategies. The aim of this study is detect, compare and analyse these mutations in NSCLC patients of a cohort of 482 cases from Karolinska University Hospital. Methods: We conducted an initial screening using pan-TRK immunohistochemistry (IHC) to analyze the material. Positive cases were further examined through whole-exome sequencing (WES) with next-generation sequencing (NGS) to confirm the presence of fusions. Additionally, to deepen our understanding, we utilized Ingenuity Pathway Analysis (IPA) software, an artificial intelligence-driven technology, to explore the molecular pathways involved in lung cancer. Results: TRK overexpression was detected in 4.56% of cases via IHC. Among 15 pan-TRK-positive cases, WES confirmed fusions in 3, revealing a higher prevalence of NTRK1 (6.6%) and NTRK2 (13.3%) fusions, while no NTRK3 fusions were observed. Conclusions: Our findings confirm the low prevalence of these neoplasms as well as the need for a molecular test to confirm rearrangements or other potentially treatable mutations and raise other questions regarding their clinical use. However, there is an acceptable correlation between pan-TRK IHC and NTRK mutations, but not enough to determine NTRK fusions.

26 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJordi Gonzalez-Molina
Jordi Gonzalez-Molina
KKKatharina Miria Kirchhof
Katharina Miria Kirchhof
BRBhavik Rathod
Bhavik Rathod
LMLidia Moyano-Galceran
Lidia Moyano-Galceran
MCMaria Calvo-Noriega
Maria Calvo-Noriega
KLKaisa Lehti
Kaisa Lehti
Fibrillar collagens promote cell proliferation, migration, and survival in various epithelial cancers and are generally associated with tumour aggressiveness. However, the impact of fibrillar collagens on soft tissue sarcoma behaviour remains poorly understood. Unexpectedly, we find here that fibrillar collagen-related gene expression is associated with favourable patient prognosis in rhabdomyosarcoma. By developing and using collagen matrices with distinct stiffness and in vivo -like microarchitectures, we uncover that the activation of DDR1 has pro-apoptotic and integrin β1 pro-survival function, specifically in 3D rhabdomyosarcoma cell cultures. We demonstrate that rhabdomyosarcoma cell-intrinsic or extrinsic matrix remodelling promotes cell survival. Mechanistically, we find that the 3D-specific collagen-induced apoptosis results from a dual DDR1-independent and a synergistic DDR1-dependent TRPV4-mediated response to mechanical confinement. Altogether, our results indicate that dense microfibrillar collagen-rich microenvironments are detrimental to rhabdomyosarcoma cells through an apoptotic response orchestrated by the induction of DDR1 signalling and mechanical confinement. This mechanism helps to explain the preference of rhabdomyosarcoma cells to grow in and metastasise to low fibrillar collagen microenvironments such as the lung.

28 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
OGOkan Gultekin
Okan Gultekin
JGJordi Gonzalez-Molina
Jordi Gonzalez-Molina
EHElin Hardell
Elin Hardell
LMLidia Moyano-Galceran
Lidia Moyano-Galceran
NMNicholas Mitsios
Nicholas Mitsios
JCJoseph Carlson
Joseph Carlson
Purpose: Uterine sarcomas are rare but deadly malignancies without effective treatment. The goal of this study was to characterize and identify potential mechanisms underlying observed variations in the immune microenvironment of different sarcoma subtypes, using integrated clinicopathological and molecular methods. Experimental design: Fifty-eight cases of uterine sarcoma with full clinicopathological annotation were analyzed for their immune landscape in the tumor microenvironment, gene, and protein expression. Cases included leiomyosarcoma (LMS; n=13), low-grade endometrial stromal sarcoma (ESS; n=16), undifferentiated uterine sarcoma (UUS; n=26), and YWHAE-FAM22 translocation-bearing ESS (YFAM; n=3). Image analysis was used to quantify immune cells and immune regulatory proteins. Gene ontology and network enrichment analysis of matching transcriptomic data was used to relate over- and under expressed genes to pathways and further to the immune phenotype and clinicopathological findings. Results: Immune cell characterization revealed overall prevalence of regulatory T cells and the pro-tumor M2-like macrophages. Cytotoxic T cells were only found in ESS and UUS tumors. Expression of immune regulatory proteins was heterogeneous, with PD-L1 being undetectable. Hierarchical clustering of patients showed four immune signatures independent of tumor type, where infiltration of non-exhausted FOXP3 + cells and M1-like macrophages were associated with greater overall survival. High CD8 + /FOXP3 + ratio in UUS and ESS was associated with poor survival and upregulation of extracellular matrix (ECM)-related genes and proteins and YAP nuclear localization. Conclusions: Uterine sarcomas present distinct immune signatures with prognostic value, independent of tumor type. This study suggests that the ECM is a potential regulator of the immune microenvironment in uterine sarcomas.

29 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJordi Gonzalez-Molina
Jordi Gonzalez-Molina
PHPaula Hahn
Paula Hahn
RFRaul Maia Falcão
Raul Maia Falcão
OGOkan Gultekin
Okan Gultekin
GKGeorgia Kokaraki
Georgia Kokaraki
JCJoseph Carlson
Joseph Carlson
Fibrillar collagen deposition, stiffness, and downstream signalling support the development of leiomyomas (LM), common benign mesenchymal tumours of the uterus, and are associated with aggressiveness in multiple carcinomas. Compared to epithelial carcinomas, however, the impact of fibrillar collagens on malignant mesenchymal tumours, including uterine leiomyosarcoma (LMS), remains elusive. In this study, we analyse the network morphology and density of fibrillar collagens combined with the gene expression of LMS, LM and normal myometrium (MM). We find that, in contrast to LM, LMS tumours present low collagen density and increased expression of collagen-remodelling genes, features associated with tumour aggressiveness. Using collagen-based 3D matrices, we show that the activity of MMP14, a central protein with collagen-remodelling functions particularly overexpressed in LMS, is necessary for LMS cell proliferation. In addition, we find that, unlike MM and LM cells, LMS proliferation and migration are not affected by collagen substrate stiffness. We demonstrate that LMS cell growth in low matrix adhesion microenvironments is supported by an enhanced basal YAP activity. Altogether, our results indicate that LMS cells acquire high collagen remodelling capabilities and are adapted to grow and migrate in low collagen and soft microenvironments. These results further suggest that matrix remodelling and YAP are potential therapeutic targets for this deadly disease.

15 July 2026 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
JHJair Manuel Gutiérrez Herrera
Jair Manuel Gutiérrez Herrera
MMM.Angeles Montero-Fernandez
M.Angeles Montero-Fernandez
GKGeorgia Kokaraki
Georgia Kokaraki
LPLuigi De Petris
Luigi De Petris
RFRaul Falcao
Raul Falcao
COCristian Ortiz-Villalón
Cristian Ortiz-Villalón
Background: Precision medicine has introduced immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) as key therapies for lung cancer. However, the interaction between PD-L1 expression and NTRK rearrangements in non-small cell lung cancer (NSCLC) remains unclear. Methods: A cohort of 482 resected NSCLC cases was analyzed using tissue microarrays. Immunohistochemistry (IHC) assessed PD-L1 expression with four antibody clones and pan-TRK with one clone. Whole-exome sequencing (WES) identified NTRK mutations, copy number variations, and gene fusions. Associations with clinicopathological features and prognosis were evaluated using Cox regression and survival analyses. Potential molecular connections between NTRK and PD-L1 were explored through a multi-database interactome analysis using Cytoscape. Results: PD-L1 positivity (TPS ≥ 1%) varied by clone: 28-8 (41.5%), 22C3 (34.2%), SP263 (42.7%), and SP142 (10.4%). High PD-L1 expression (TPS ≥ 50%) correlated with poorer overall survival in SP142-assessed cases (p = 0.045). TRK expression was observed in 4.6% (22/482) of cases, predominantly in squamous cell carcinoma (72.7%). Co-expression of pan-TRK and PD-L1 was significant (p < 0.001), with 4.6% of tumors showing dual positivity. WES detected three NTRK rearrangements, with no direct association with survival. Conclusions: The co-expression of PD-L1 and pan-TRK observed in this cohort suggests a biologically relevant interaction that warrants further investigation into its potential role in treatment response and resistance mechanisms to ICIs and TKIs.